

A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose[§]

Iain J. Martin, Susan E. Hill,¹ James A. Baker, Sujal V. Deshmukh,¹ and Erin F. Mulrooney

Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck Research Laboratories, Boston, Massachusetts

Received March 7, 2016; accepted June 2, 2016

ABSTRACT

A preclinical drug candidate, MRK-1 (Merck candidate drug parent compound), was found to elicit tumor regression in a mouse xenograft model. Analysis of samples from these studies revealed significant levels of two circulating metabolites, whose identities were confirmed by comparison with authentic standards using liquid chromatography-tandem mass spectrometry. These metabolites were found to have an *in vitro* potency similar to that of MRK-1 against the pharmacological target and were therefore thought to contribute to the observed efficacy. To predict this contribution in humans, a pharmacokinetic (PK) modeling approach was developed. At the mouse efficacious dose, the areas under the plasma concentration time curves (AUCs) of the active metabolites were normalized by their *in vitro* potency compared with MRK-1. These

normalized metabolite AUCs were added to that of MRK-1 to yield a composite efficacious unbound AUC, expressed as “parent drug equivalents,” which was used as the target AUC for predictions of the human efficacious dose. *In vitro* and preclinical PK studies afforded predictions of the PK of MRK-1 and the two active metabolites in human as well as the relative pathway flux to each metabolite. These were used to construct a PK model (Berkeley Madonna, version 8.3.18; Berkeley Madonna Inc., University of California, Berkeley, CA) and to predict the human dose required to achieve the target parent equivalent exposure. These predictions were used to inform on the feasibility of the human dose in terms of size, frequency, formulation, and likely safety margins, as well as to aid in the design of preclinical safety studies.

Introduction

During drug discovery, predictions of human pharmacokinetics (PK) and efficacious dose are important for making decisions about the probability of success of clinical development of a compound. Increasingly, such predictions are made as part of an integrated translational pharmacology strategy (Bueters et al., 2015). Various methods for human PK predictions have been developed and refined, incorporating a range of *in silico*, *in vitro*, and preclinical *in vivo* data, and there are many excellent reviews on the subject (Obach et al., 1997; Lombardo et al., 2013a,b). An understanding of metabolism and other clearance mechanisms *in vitro* and in preclinical species and how they translate to the clinic is a pivotal component of these predictions. Drug metabolites can not only cause or contribute to drug-drug interactions (Rambeck et al., 1990; Ho et al., 2003; Isoherranen et al., 2009; Yu and Tweedie, 2013; Yu et al., 2015) and other safety concerns (Bauman et al., 2008), but can also potentially contribute to efficacy (Drayer, 1976; Fura, 2006; Obach 2013). In such cases, predictions of human efficacious dose should include the contribution of active metabolites to efficacy.

In the current work, an oncology candidate compound (MRK-1) elicited tumor regression in a mouse xenograft model after repeated oral administration. It was apparent from *in vitro* and *in vivo* data that this compound, in common with most of the chemical series, underwent metabolism to produce significant levels of circulating metabolites.

Since some of these metabolites [active metabolite 1 of MRK-1 (M1) and active metabolite 2 of MRK-1 (M2)] were known to possess significant *in vitro* potency, it was important to assess their potential contribution to the observed efficacy in the mouse and how this might translate to the clinic. This would inform on projections of a clinical efficacious dose as well as serve to guide any further optimization strategy. Here, an approach is described to quantifying the contribution of active metabolites to mouse efficacy and incorporating this into a model (built using Berkeley Madonna, version 8.3.18; Berkeley Madonna Inc., University of California, Berkeley, CA) to predict the human PK and efficacious dose. The objective of building this model was to provide a fit-for-purpose tool that the program team could use to predict the human efficacious dose, and to assess its feasibility in terms of size, frequency, formulation, and likely safety margins. Since the model output provided a predicted PK profile of both the drug and the active metabolites, it was also used to aid the design of preclinical safety studies. The model facilitated interrogation of various “what if” scenarios and was applied to other molecules over the course of the drug discovery program. The approach and model are generally applicable to active metabolite scenarios, and the full executable model code has been made available (Supplemental Material).

Materials and Methods

In this section, the focus will be on the approach used to predict and incorporate the contribution of active metabolites to the human efficacious dose together with a detailed description of the PK model. The full model code is available in the Supplemental Material and can be executed in Berkeley-Madonna via simple copying and pasting. We will give only a brief overview of the methodology used

¹Current affiliation: Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.

dx.doi.org/10.1124/dmd.116.070391.

[§]This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: AUC, area under the plasma concentration time curve; CL, plasma clearance; f_{abs}, oral fraction absorbed; k_a, absorption rate constant; LC-MS/MS, liquid chromatography-tandem mass spectrometry; M1, active metabolite 1 of MRK-1; M2, active metabolite 2 of MRK-1; MRK-1, Merck candidate drug parent compound; *m/z*, charge-to-mass ratio; PK, pharmacokinetics; V_{ss}, volume of distribution at steady state.

to generate the model inputs since the precise details are not central to the applicability of the approach and the model. Other researchers can follow the approach and use the model by generating the appropriate model inputs using their own preferred methods.

Assumptions and Approach. It was assumed that efficacy was driven by free drug and that free drug concentrations in plasma were a surrogate for those in the tumor. Further, since *in vitro* potencies for the parent drug and active metabolites were within a 2.5-fold range, mutual competitive inhibition was not invoked. Rather, it was assumed that an efficacious response (tumor regression) could be equally driven by the parent drug or an equivalent combined concentration of the parent drug and active metabolites. The primary route of elimination for all three molecules was assumed to be via hepatic metabolism, and the systemic availability of M1 and M2 was assumed to be 1.

The mouse steady-state unbound areas under the plasma concentration time curve (AUCs) of the active metabolites at the efficacious dose were normalized by their *in vitro* potency relative to the parent compound. These normalized metabolite AUCs were added to that of the parent drug to yield a composite efficacious unbound AUC expressed in terms of “parent drug equivalents.” This AUC was used as the target exposure for predictions of the human efficacious dose. *In vitro* and preclinical PK studies afforded predictions of the PK parameters of the parent compound and the two active metabolites in humans, as well as the relative metabolic pathway flux to each of the active metabolites. These predictions were combined with the relative *in vitro* potencies of the parent compound and the active metabolites in humans to parameterize a PK model and to estimate the human dose required to achieve the target parent equivalents exposure.

Model Structure. A system of differential equations was constructed in Berkeley Madonna (version 8.3.18; Berkeley Madonna Inc.) to represent the flux through the proposed metabolic pathways (Fig. 1). A schematic of the model structure is presented in Fig. 2, and the full model code is available (Supplemental Material). An overview of the generation of the model inputs is given below, and these are summarized, together with their numerical values, in Table 1. Readers can execute the model code by copying and pasting from the Supplemental Material directly into a blank Berkeley Madonna equations page. Furthermore, the approach and model are generally applicable, and the reader may transpose them to their own active metabolite scenario by consideration of Fig. 2, creation of the appropriate model structure, and subsequent editing of the model code.

Overview of Generation of Model Input Data. All animal studies were performed using protocols approved by the Merck Institutional Animal Care and Use Committee.

The putative metabolic pathway of MRK-1, M1, and M2 was elucidated by high-resolution mass spectrometry and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of incubates generated in microsomes and hepatocytes (rat, dog, human) and recombinant human cytochromes P450, as well as of plasma from PK studies (rat, dog).




Fig. 1. Proposed metabolic pathway of MRK-1 derived from *in vitro* (hepatocytes) and *in vivo* (plasma from PK studies) data.

The primary *in vitro* potencies of MRK-1, M1 and M2 at the pharmacological target were determined by immobilized metal ion affinity–based fluorescence polarization using the phosphorylated active human enzyme. The *in vivo* efficacy of MRK-1 was assessed in a mouse xenograft model in which human-derived tumor cells were implanted into the flank of female CD1 nude mice. After a 3-week tumor-establishing period, MRK-1 was administered as a suspension by oral gavage at 25, 50, and 100 mg/kg twice a day for 21 days ($n = 5$ per dose group). On day 21, mice were sacrificed at 2, 4, 6, 9, and 24 hours; blood samples were collected, and tumors were excised. Blood samples were centrifuged to yield plasma, which was then analyzed by LC-MS/MS to quantify MRK-1, M1, and M2. Tumors were measured using calipers, and tumor volume was calculated according to the following algorithm: volume = $1/2(\text{length} \times \text{width squared})$. The efficacious dose was considered to be the minimum dose level that elicited tumor regression over the time course of the study.

The *in vitro* intrinsic clearances of MRK-1, M1, and M2 were determined in cryopreserved rat, dog, and human hepatocytes using a standard substrate depletion method (Naritomi et al., 2003), and were quantified via LC-MS/MS. Compounds were incubated for 120 minutes at 0.3 μM in Krebs-Henseleit buffer containing 2×10^6 hepatocytes/ml, and the initial slope of the substrate disappearance curve (\ln peak area ratio versus time) was used to calculate the intrinsic clearance. For MRK-1, M1, and M2, the contributions of the pathways yielding the active metabolites (MRK-1 \rightarrow M1 and M2; M1 \rightarrow M2; M2 \rightarrow M1) were estimated by monitoring the metabolite appearance in cryopreserved rat, dog, and human hepatocytes at a substrate concentration of 1 μM . Metabolite concentrations were quantified by LC-MS/MS using a standard curve prepared from authentic standards, and the initial metabolite formation rate was calculated from the linear portion of the appearance curve. This rate was divided by the substrate concentration to yield an estimate of formation intrinsic clearance. The fractional contribution of each metabolite to the total elimination was determined by dividing its formation intrinsic clearance by the depletion intrinsic clearance of its parent molecule. Any substrate depletion intrinsic clearance not accounted for by formation of the monitored metabolites was assigned to pathways resulting in inactive metabolites.

Plasma protein binding of MRK-1, M1, and M2 was determined in mouse, rat, dog, and human plasma by equilibrium dialysis using the HTDialysis apparatus (HTDialysis LLC, Gales Ferry, CT); compounds were incubated for 6 hours at a concentration of 1 μM . Blood-to-plasma ratios were determined in fresh mouse, rat, dog, and human blood using the indirect method (Yu et al., 2005); compounds were incubated for 0.5 hour at a concentration of 1 μM .

The PK of MRK-1, M1, and M2 in rat and dog were determined after single intravenous (0.5 mg/kg; 1.5 $\mu\text{mol/kg}$) and single oral (1.0 mg/kg; 3.1 $\mu\text{mol/kg}$) administration. Plasma from serial blood samples was analyzed quantitatively by LC-MS/MS. Plasma samples were prepared for analysis by means of a single-step protein precipitation technique by adding 200 μl of internal standard crashing solvent (labetalol, alprazolam, and diclofenac in acetonitrile) to 50- μl aliquots of plasma. Samples were mixed by vortex for homogeneity and then subjected to centrifugation for 10 minutes at 400 rpm. The supernatant (200 μl) was then transferred into new 96-well plates and injected into the LC-tandem mass spectrometer for analysis. Chromatography was carried out by means of LX-2




Fig. 2. Schematic of the PK model constructed in Berkeley Madonna to predict the human pharmacokinetics of MRK-1, M1, and M2.

TABLE 1

Data inputs, designations in model script, and numerical values used for partial model qualification (dog) and prediction of MRK-1 efficacious dose (human)

Data Input	Molecules	Designation in Model	Value (Human)	Value (Dog)
Fraction of MRK-1 parent eliminated to M1	MRK-1, M1	f_p_m1	0.93	0.44
Fraction of MRK-1 parent eliminated to M2	MRK-1, M2	f_p_m2	0.02	0.04
Fraction of MRK-1 parent eliminated to inactive metabolites*	MRK-1	f_p_xxx	0.05	0.52
Fraction of M1 eliminated to M2	M1, M2	f_m1_m2	0.08	0.00
Fraction of M1 eliminated to inactive metabolites*	M1	f_m1_xxx	0.92	1.00
Fraction of M2 eliminated to M1	M1, M2	f_m2_m1	0.73	1.00
Fraction of M2 eliminated to inactive metabolites	M2	f_m2_xxx	0.27	0.00
ka	MRK-1	Kap	1.0/h	2.9/h
Fabs	MRK-1	fabs	1.0	1.0
CL	MRK-1	CLp	4.8 ml/min/kg	10.1 ml/min/kg
CL	M1	CLm1	1.9 ml/min/kg	1.6 ml/min/kg
CL	M2	CLm2	8.6 ml/min/kg	17.7 ml/min/kg
Volume of distribution	MRK-1	V1p	2.3 l/kg	1.0 l/kg
Volume of distribution	M1	V1m1	1.6 l/kg	1.1 l/kg
Volume of distribution	M2	V1m2	2.6 l/kg	2.1 l/kg
Elimination rate constant*	MRK-1	kep	0.125/h	0.61/h
Elimination rate constant*	M1	kem1	0.071/h	0.087/h
Elimination rate constant*	M2	kem2	0.198/h	0.51/h
Fraction unbound in plasma	MRK-1	fup	0.129	0.120
Fraction unbound in plasma	M1	fum1	0.238	0.238
Fraction unbound in plasma	M2	fum2	0.209	0.190
In vitro target binding potency	MRK-1	p_IC50	1.2 nM	NA
In vitro target binding potency	M1	m1_IC50	1.8 nM	NA
In vitro target binding potency	M2	m2_IC50	0.7 nM	NA
Molecular weight	MRK-1	mwp	324.38 Da	324.38 Da
Molecular weight	M1	mwm1	296.33 Da	296.33 Da
Molecular weight	M2	mwm2	338.36 Da	338.36 Da
Target unbound exposure for efficacy	MRK-1, M1, M2	TargAUCuUM410equivs	16.8 μ M/h	NA

NA, not applicable to model qualification.

*Values calculated within the model.

Thermo Cohesive systems equipped with Allegro pumps (ThermoFisher Scientific Inc., Cambridge, MA). Separation was performed on an Acquity HSS T3 column (2.1 \times 50 mm, 1.8 μ m; Waters, Milford, MA) at room temperature with an injection volume of 5 μ l. The mobile phase consisting of solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile) was delivered at a flow rate of 750 μ l/min. The LC gradient started from 95/5 [solvent A/solvent B (A/B)] and changed to 5/95 (A/B) from 0.25 to 1.75 minutes (ramp), remaining constant at this ratio for 0.5 minute. The gradient decreased to 95/5 (A/B) from 2.25 to 2.65 minutes (ramp), remaining constant at this ratio for 0.8 minute. Detection was carried out using an API5000 triple quadrupole tandem mass spectrometer equipped with an electrospray interface (Applied Biosystems, Foster City, CA). Ions were created in the positive ion mode by setting the sprayer voltage at 5.0 kV and the ion source temperature at 500°C. The common parameters and the nitrogen flow values for nebulizer gas (Gas 1), auxiliary gas (Gas 2), curtain gas, and the gas for collision-activated dissociation were set at 60, 60, 35, and 5, respectively. Detection of the analytes was performed in the multiple reaction-monitoring mode, and the following precursor to product ion pairs, declustering potentials (DP) and collision energies (CE) were used for quantitation: mass-to-charge ratio (m/z) 325.3 \rightarrow 221.2 for MRK-1 (DP/CE: 100 V/20 eV); m/z 297.4 \rightarrow 193.3 for M1 (DP/CE: 80 V/20 eV); and m/z 339.1 \rightarrow 235.2 for M2 (DP/CE: 100 V/25 eV). The following multiple reaction-monitoring transitions were monitored for the internal standard: 329.2 \rightarrow 162.1 for labetalol, 309.0 \rightarrow 205.0 for alprazolam, and 296.0 \rightarrow 214.0 for diclofenac. Peak area ratios of the analyte to internal standard (labetalol) were used for construction of the calibration curve. A weighting of $1/x^2$ (least-squares linear regression analysis, where x is the concentration of a given standard) was used for curve fit. Concentrations in unknown samples were calculated from the best-fit equation ($y = mx + b$), where y is the peak area ratio. Noncompartmental analysis afforded estimates of plasma clearance (CL), volume of distribution at steady state (V_{ss}), absorption rate constant (ka), and bioavailability. The oral fraction absorbed (fabs) was estimated from bioavailability and CL, assuming CL to be exclusively hepatic with liver blood flows of 84 ml/min/kg (rat) and 31 ml/min/kg (dog).

The CL values of MRK-1, M1, and M2 in humans were predicted by a range of techniques, as follows: single-species allometry (Tang et al., 2007); scaling of in vitro intrinsic clearance using physiologic scaling factors; and the well-stirred

liver model (Ito and Houston, 2004), and hybrid allometry (Lavé et al., 1999). The predicted human V_{ss} was derived from the mean of the unbound V_{ss} in rat and dog corrected for human plasma protein binding. The human ka of MRK-1 was assumed to be 1/h, and human fabs after oral administration of MRK-1 was assumed to be equivalent to that estimated from rat PK data.

Partial Qualification of the Model in the Dog. The ability of the model to predict the observed PK in dog was assessed. The metabolite pathway flux approach was applied to the dog in a manner analogous to that used for the human predictions. Estimated ka , fabs, CL, and V_{ss} values were obtained from PK studies, as described above. CL and V_{ss} were used to derive elimination rate constants, and these were then fractionated according to the relative pathway flux determined in dog hepatocytes. The dog data inputs used in the model are summarized in Table 1. The model was used to predict the plasma concentrations and AUCs of MRK-1, M1, and M2 after oral administration of MRK-1.

Results

Metabolism of MRK-1, M1, and M2. Based on in vitro and in vivo studies, a putative metabolic pathway for MRK-1 was proposed (Fig. 1). MRK-1 was found to be *N*-dealkylated to form M1, which then underwent *N*-acetylation to form M2. M2 was also found to be formed directly from MRK-1 in microsomes and recombinant cytochromes P450. The ability of M2 to be formed both directly or via M1 was also indicated from in vitro studies using MRK-1 with a fully deuterated ethyl side chain (data not shown). The formation of M2 from M1 was also found to occur in rat blood during the assay to determine blood-to-plasma partitioning. This pathway was not observed in blood from dog or human. The conversion of M1 to M2 did not occur in dog hepatocytes. Quantitative data from human hepatocytes suggested that MRK-1 was metabolized predominantly to M1 and that M1 itself was metabolized mainly to inactive metabolites. The small amount of M2 formed either directly from MRK-1 or via M1 was predicted to be metabolized back to M1. The predicted fractional pathways in humans are given in Table 1.

Partial Qualification of the Model in the Dog. Unbound plasma AUCs of MRK-1, M1, and M2 in the dog after oral administration of MRK-1 were compared with the predictions from the model. The comparison of plasma profiles is shown in Fig. 3. Predicted plasma concentrations of MRK-1 were similar to the observed values, resulting in a predicted-to-observed AUC ratio of 1.01. For both M1 and M2, predicted plasma concentrations were lower than those observed with predicted-to-observed AUC ratios of 0.60 (M1) and 0.63 (M2).

Prediction of the Human Efficacious Dose of MRK-1. Using the model inputs detailed in Table 1, including a target efficacious unbound AUC of $16.8 \mu\text{M} \cdot \text{h}$ MRK-1 equivalents, the human efficacious dose of MRK-1 was predicted to be 2.7 mg/kg (8.2 $\mu\text{mol}/\text{kg}$) once daily; equivalent to approximately 187 mg (576 μmol for a 70 kg individual). The predicted relative contributions of MRK-1, M1, and M2 to the target efficacious unbound exposure were 22%, 75%, and 3%, respectively, and the predicted plasma profiles are shown in Fig. 4.

Discussion

Active metabolites that contribute significantly to efficacy likely result in increased complexity for drug development, including additional bioanalytical work to quantify metabolites and increasingly complex PK/pharmacodynamic analyses. Indeed, it has been suggested that the formation of active metabolites must be avoided (Nassar et al., 2004), and their potential role in variable clinical response has been categorized as one reason for the discontinuation of drug development under the heading of “inappropriate pharmacokinetics” (Smith et al., 1996). Nonetheless, there are numerous examples of drugs where the pharmacology is either dominated by metabolites or the metabolites contribute significantly (Obach, 2013). There are also many cases of active metabolites being developed as drugs owing to superior pharmacological, PK, or safety profiles compared with the parent molecule (Fura et al., 2004). It has been proposed that interest in stable circulating metabolites from a purely toxicological standpoint will decline (Smith and Obach, 2010), since, at the time of their writing, there were few examples of linkage to toxicity outside of the pharmacology of the parent. Furthermore, it has been suggested that the risk of a metabolite being the sole perpetrator of a P450 inhibition-based drug-drug interactions is low (Yu et al., 2015). Nonetheless, regulatory guidelines exist for the characterization of human metabolites according to whether they are deemed to have been adequately tested during preclinical toxicology

[Food and Drug Administration, 2012 (<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079266.pdf>); International Conference on Harmonization, 2012 (<http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html>)]. Partially as a consequence of these guidelines, there has been much research into the prediction, detection, and quantification of human circulating metabolites (Anderson et al., 2009; Dalvie et al., 2009; Leclercq et al., 2009; Pelkonen et al., 2009; Lutz et al., 2010; Luffer-Atlas, 2012; Loi et al., 2013). The theoretical basis for predicting metabolite exposure has been discussed by Lutz et al. (2010). Perhaps driven by regulatory considerations, such efforts have largely been aimed at predicting the AUC ratio of metabolite to parent. The authors acknowledged that some pharmacologic or toxicologic endpoints might be C_{max} driven, and that predictions of metabolite C_{max} would require additional in vivo data on the metabolite. Recently, Nguyen et al. (2016) described a mechanistic approach for predicting the pharmacokinetics of midazolam and its metabolites using in vitro data and a physiologically based pharmacokinetic model. The predicted AUC ratios of metabolite (1-OH and 4-OH midazolam) to parent drug were in good agreement with clinical observations, and the model also afforded predicted plasma concentration versus time curves of midazolam and its metabolites. In the current study, since the metabolites were synthetically available, the model was parameterized so as to yield predictions of the full PK profile enabling risk versus benefit assessments to be made in the context of a life-threatening disease and with metabolites likely contributing significantly to efficacy. The approach and model provided a pragmatic means to assess the feasibility of developing the parent molecule in terms of dose size and frequency as well as to evaluate follower molecules with a similar potential for active metabolites. The model also facilitated the selection of toxicology species and dose levels toward establishing safety margins for the parent and its metabolites. The full executable model code is available (Supplemental Material) and may also be edited to explore other active metabolite scenarios, as described in *Materials and Methods*. However, in cases where the potency of the parent drug and active metabolites diverge more than in the current work, or where simulations of different degrees of receptor occupancy or efficacy are required, it is advised to incorporate mutual competitive inhibition into the model (Ito et al., 1993; Zhang et al., 2009).




Fig. 3. Plasma concentrations of MRK-1, M1, and M2 observed after single oral administration of MRK-1 to dogs (1 mg/kg; 3.1 $\mu\text{mol}/\text{kg}$; mean of $n = 3$), and predicted using the Berkeley Madonna PK model.




Fig. 4. Predicted unbound plasma concentrations of MRK-1, M1, and M2 in humans after once-daily oral administration (187 mg to 70 kg individual = 2.7 mg/kg; 8.2 $\mu\text{mol}/\text{kg}$).

By visual inspection, the model provided a reasonable prediction of the observed PK of MRK-1, M1, and M2 in the dog (Fig. 3) with AUC ratios (predicted to observed) of 1.01 (MRK-1), 0.60 (M1), and 0.63 (M2). Since MRK-1 was the compound administered, the model would have been expected to provide a good prediction of the observed data for MRK-1. However, inspection of Fig. 3 suggests that concentrations at early timepoints are overpredicted, whereas at later timepoints they are underpredicted. Inaccuracies in the noncompartmental parameter estimates (k_a , CL, and V_{ss}) as well in the estimation of f_{abs} are likely to have contributed to these deviations. For M1 and M2, the formation rate intrinsic clearances in hepatocytes were usually derived from only the zero and first time point. It is possible that this contributed to the observed underprediction of M1 and M2 concentrations in the dog and may also impact the human predictions; in future work of this type, a richer sampling protocol is indicated. A further potential source of error would be any clearance by nonhepatic metabolic mechanisms, as this is not accounted for in the model. Analysis of urine and bile samples from studies in bile duct-cannulated rats and dogs (data not shown) suggested that MRK-1 was eliminated almost exclusively as metabolites. However, this does not rule out the potential for uptake-mediated clearance of MRK-1, and there are no data available on the *in vivo* clearance pathways for M1 and M2. The lack of conversion of M1 to M2 in dog hepatocytes was consistent with known *N*-acetylation species differences (Tibbitts, 2003; Gao et al., 2006; Loureiro et al., 2013). Further qualification of the PK model using rat data would therefore clearly have been desirable; however, the metabolism of M1 to M2 observed in rat blood, but not in dog or human blood, rendered such a validation questionable both in terms of feasibility and value. Since the *in vivo* efficacy model was available only in the mouse, it was not possible to validate the dose prediction in another species. However, as such a model would employ human tumor cell lines in common with the mouse model, it would perhaps not be a true test of translatability. A further assumption of the model was that free plasma concentrations of MRK-1, M1 and M2 were a surrogate for the efficacious intratumoral concentrations. *In vitro* studies into the potential for active transport were inconclusive (data not shown), and no data were available on the expression of drug transporters in the tumor cell line. Therefore, the relationship between plasma and tumor-free drug levels is unknown but would be an area of focus for a more mechanistic understanding of the system. Despite these limitations, based on the partial qualification using data from the dog, and with the assumption that hepatic metabolism is the major clearance pathway for MRK-1, M1, and M2, the metabolic pathway fractionation approach and the model were deemed to be fit for the purpose in a drug discovery setting.

For MRK-1, the predicted efficacious dose of 187 mg, once daily, was deemed to be feasible for further development with a sufficient margin for error. As in the dog, the prediction accuracy may have been affected by issues such as inaccuracies in the estimation of formation rate intrinsic clearances and clearance by nonhepatic metabolic mechanisms. In addition, the model did not take into account the possibility of first-pass extraction of MRK-1 by the gut, and this is a potential area for future work to strengthen the model. The model predicted that the majority of the clinical efficacy would be driven by M1, and, as such, MRK-1 may be thought of as a prodrug even though it is active in its own right. M2 was predicted to contribute only 3% of the efficacious exposure equivalents, consistent with its relatively low fractional formation (0.02 from MRK-1 and 0.08 from M1; Table 1) and subsequent metabolism back to M1. The predicted elimination rate constants (Table 1) suggest that the half-life of M1 would be approximately 10 hours in humans, compared with 5.5 hours for MRK-1, yielding a combined profile more suited to once-daily administration than for MRK-1 without active metabolites. Conversion to the active M1

may therefore be deemed to be a very beneficial feature of MRK-1, both in terms of required dose size and administration frequency. In the model, either turning off the conversion of MRK-1 to M1 or making M1 pharmacologically inactive each yielded a predicted human efficacious dose of approximately 800 mg of MRK-1 daily, which is much less feasible from a formulation and development perspective. In this scenario, the predicted peak concentrations of MRK-1 are some 4-fold to 5-fold higher, with the potential for a greater safety risk. To ameliorate these issues, it is likely that MRK-1, without its active metabolite, would be a twice-daily drug.

In conclusion, the modeling approach described here facilitated a pragmatic prediction of the contribution of active metabolites to clinical efficacy for a discovery stage compound. The model afforded predictions of the clinically efficacious dose and was instrumental in the design of preclinical safety studies. Furthermore, the model was used to test “what if” scenarios and helped to guide further optimization of this chemical series within the discovery program.

Acknowledgments

We thank the many members of Merck Research Laboratories who contributed to this work.

Authorship Contributions

Participated in research design: Martin, Hill, Baker, Deshmukh, and Mulrooney

Conducted experiments: Hill and Mulrooney

Contributed new reagents or analytic tools: Hill and Mulrooney

Performed data analysis: Martin, Hill, and Mulrooney

Wrote or contributed to the writing of the manuscript: Martin, Hill, Baker, Deshmukh, and Mulrooney

References

- Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? *Chem Res Toxicol* **22**:243–256.
- Bauman JN, Frederick KS, Sawant A, Walsky RL, Cox LM, Obach RS, and Kalgutkar AS (2008) Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. *Drug Metab Dispos* **36**:1016–1029.
- Bueters T, Gibson C, and Visser SA (2015) Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. *Future Med Chem* **7**:2351–2369.
- Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, and Bu HZ, et al. (2009) Assessment of three human *in vitro* systems in the generation of major human excretory and circulating metabolites. *Chem Res Toxicol* **22**:357–368.
- Drayer DE (1976) Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. *Clin Pharmacokinet* **1**:426–443.
- Fura A (2006) Role of pharmacologically active metabolites in drug discovery and development. *Drug Discov Today* **11**:133–142.
- Fura A, Shu YZ, Zhu M, Hanson RL, Roongta V, and Humphreys WG (2004) Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. *J Med Chem* **47**:4339–4351.
- Gao W, Johnston JS, Miller DD, and Dalton JT (2006) Interspecies differences in pharmacokinetics and metabolism of *S*-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-*N*-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of *N*-acetyltransferase. *Drug Metab Dispos* **34**:254–260.
- Ho PC, Abbott FS, Zanger UM, and Chang TK (2003) Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. *Pharmacogenomics J* **3**:335–342.
- Isoherranen N, Hachad H, Yeung CK, and Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. *Chem Res Toxicol* **22**:294–298.
- Ito K and Houston JB (2004) Comparison of the use of liver models for predicting drug clearance using *in vitro* kinetic data from hepatic microsomes and isolated hepatocytes. *Pharm Res* **21**:785–792.
- Ito K, Yamada Y, Nakamura K, Sawada Y, and Iga T (1993) Classification of benzodiazepine hypnotics in humans based on receptor occupancy theory. *J Pharmacokin Biopharm* **21**:31–41.
- Lavé T, Coassolo P, and Reigner B (1999) Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and *in vitro-in vivo* correlations. *Clin Pharmacokinet* **36**:211–231.
- Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, and Evans DC (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. *Chem Res Toxicol* **22**:280–293.
- Loi CM, Smith DA, and Dalvie D (2013) Which metabolites circulate? *Drug Metab Dispos* **41**:933–951.
- Lombardo F, Waters NJ, Argikar UA, Dennehy MK, Zhan J, Gunduz M, Harriman SP, Berellini G, Rajlic IL, and Obach RS (2013a) Comprehensive assessment of human pharmacokinetic

- prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. *J Clin Pharmacol* **53**:167–177.
- Lombardo F, Waters NJ, Argikar UA, Dennehy MK, Zhan J, Gunduz M, Harriman SP, Berellini G, Liric Rajlic I, and Obach RS (2013b) Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. *J Clin Pharmacol* **53**: 178–191.
- Loureiro AI, Fernandes-Lopes C, Bonifácio MJ, Wright LC, and Soares-da-Silva P (2013) N-acetylation of etamicastat, a reversible dopamine- β -hydroxylase inhibitor. *Drug Metab Dispos* **41**:2081–2086.
- Luffer-Atlas D (2012) The early estimation of circulating drug metabolites in humans. *Expert Opin Drug Metab Toxicol* **8**:985–997.
- Lutz JD, Fujioka Y, and Isoherranen N (2010) Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. *Expert Opin Drug Metab Toxicol* **6**:1095–1109.
- Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. *Drug Metab Dispos* **31**:580–588.
- Nassar AE, Kamel AM, and Clarimont C (2004) Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. *Drug Discov Today* **9**: 1020–1028.
- Nguyen HQ, Kimoto E, Callegari E, and Obach RS (2016) Mechanistic modeling to predict midazolam metabolite exposure from in vitro data. *Drug Metab Dispos* **44**:781–791.
- Obach RS (2013) Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. *Pharmacol Rev* **65**:578–640.
- Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. *J Pharmacol Exp Ther* **283**:46–58.
- Pelkonen O, Tolonen A, Korjamo T, Turpeinen M, and Raunio H (2009) From known knowns to known unknowns: predicting in vivo drug metabolites. *Bioanalysis* **1**:393–414.
- Rambeck B, Sälke-Treumann A, May T, and Boenigk HE (1990) Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents. *Eur Neurol* **30**:79–83.
- Smith DA, Jones BC, and Walker DK (1996) Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. *Med Res Rev* **16**:243–266.
- Smith DA and Obach RS (2010) Metabolites: have we MIST out the importance of structure and physicochemistry? *Bioanalysis* **2**:1223–1233.
- Tang H, Hussain A, Leal M, Mayersohn M, and Fluhler E (2007) Interspecies prediction of human drug clearance based on scaling data from one or two animal species. *Drug Metab Dispos* **35**: 1886–1893.
- Tibbitts J (2003) Issues related to the use of canines in toxicologic pathology—issues with pharmacokinetics and metabolism. *Toxicol Pathol* **31** (Suppl):17–24.
- Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, Mao J, Lai WG, Lee AJ, and Lim HK, et al. (2015) Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group. *Drug Metab Dispos* **43**:620–630.
- Yu S, Li S, Yang H, Lee F, Wu JT, and Qian MG (2005) A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. *Rapid Commun Mass Spectrom* **19**:250–254.
- Yu H and Tweedie D (2013) A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency. *Drug Metab Dispos* **41**:536–540.
- Zhang X, Jones DR, and Hall SD (2009) Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. *Drug Metab Dispos* **37**: 150–160.

Address correspondence to: Iain J. Martin, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115. E-mail: iain.martin@merck.com

TITLE: A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose

AUTHORS: Iain J. Martin, Susan E. Hill, James A. Baker, Sujal V. Deshmukh and Erin F. Mulrooney

JOURNAL: Drug Metabolism and Disposition

Supplemental Material 1

Executable code to run the PK model. All text below should be copied and pasted into a blank equations window with Berkeley-Madonna. User can customize plots and sliders according to requirements.

{-----}

{Integration parameters and time steps}

METHOD Stiff
STARTTIME=0
STOPTIME=500
DT = 0.01
DOUT = 0.0001
DTMAX=0.001

{-----}

{Initialize amounts}

INIT D = 0 ;D is used as a dosing compartment to represent the gut
INIT A1p = 0 ;amount of MRK-1 in central compartment
INIT A1m1 = 0 ;amount of MRK-1 in central compartment
INIT A1m2 = 0 ;amount of MRK-1 in central compartment

{-----}

{Fractional elimination pathways}

f_p_m1 = 0.93 ;fraction of MRK-1 eliminated to M1
f_p_m2 = 0.02 ;fraction of MRK-1 eliminated to M2
f_p_xxx = 1-(f_p_m1 + f_p_m2) ;fraction of MRK-1 eliminated to inactive metabolites

f_m1_m2 = 0.08 ;fraction of M1 eliminated to M2
f_m1_xxx = 1-(f_m1_m2) ;fraction of M1 eliminated to inactive metabolites

f_m2_m1 = 0.73 ;fraction of M2 eliminated to M1
f_m2_xxx = 1-(f_m2_m1) ;fraction of M2 eliminated to inactive metabolites

{-----}

{Dosing regimen}

FirstT=0 ;time of dose regimen start
DoseNum = 10 ;number of doses to simulate
RepeatT=12 ;dosing interval
EndT=(RepeatT*DoseNum) ;time of dose regimen end

DoseTrue=(TIME<EndT) AND (TIME>FirstT) ;test for regimen being active

{Function to deliver dose to dosing compartment according to regimen}

DosePulse=PULSE(DOSE,FirstT,RepeatT)

{-----}
{Differential equations for change of amount}

{Dosing compartment = gut}
d/dt(D)=IF(DoseTrue)THEN(DosePulse-Absorption)ELSE(-Absorption)

{MRK-1 in central compartment}
d/dt(A1p)=Absorption-(kep*A1p*f_p_m1)-(kep*A1p*f_p_m2)-(kep*A1p*f_p_xxx)

{M1 in central compartment}
d/dt(A1m1) = (kep*A1p*f_p_m1)-(kem1*A1m1*f_m1_m2)-
(kem1*A1m1*f_m1_xxx)+(kem2*A1m2*f_m2_m1)

{M2 in central compartment}
d/dt(A1m2) = (kep*A1p*f_p_m2)+ (kem1*A1m1*f_m1_m2)-(kem2*A1m2*f_m2_m1)-
(kem2*A1m2*f_m2_xxx)

{-----}
{Amounts & Concentrations}

CONCp= A1p/(V1p*1000) ;concentration of MRK-1 in plasma
CONCm1 = A1m1/(V1m1*1000) ;concentration of M1 in plasma
CONCm2 = A1m2/(V1m2*1000) ;concentration of M1 in plasma

{Convert to unbound plasma concentrations}
CONCup = CONCp*fup
CONCum1 = CONCm1*fum1
CONCum2 = CONCm2*fum2

{-----}
{Other parameter values}

{MRK-1}
Kap = 1 ;absorption rate constant h-1
Absorption = Kap*D ;absorption rate for use in differential eqns above
Kep =(CLp*60)/(V1p*1000) ;total elimination rate constant h-1
CLp=4.8 ;plasma clearance ml/min/kg
V1p=2.3 ;volume of distribution L/kg
fup = 0.129 ;fraction unbound in plasma

ADOSE=3.18 ;administered dose mg/kg
DOSE=fabs*ADOSE*1000000 ;absorbed dose ng/kg
fabs=1.0 ;fraction absorbed

{M1}
Kem1 =(CLm1*60)/(V1m1*1000) ;total elimination rate constant h-1
CLm1 = 1.9 ;plasma clearance ml/min/kg
V1m1= 1.6 ;volume of distribution L/kg
fum1 = 0.238 ;fraction unbound in plasma

{M2}

$Kem2 = (CLm2 * 60) / (V1m2 * 1000)$;total elimination rate constant h-1
 $CLm2 = 8.6$;plasma clearance ml/min/kg
 $V1m2 = 2.6$;volume of distribution L/kg
 $fum2 = 0.209$;fraction unbound in plasma

{-----}
{Calculation of average concentration in last dose interval and AUC}

{Function to test for being in the last dosing interval}
 $LastDoseStart = (DoseNum * RepeatT) - RepeatT$
 $LastDoseEnd = (DoseNum * RepeatT)$
 $LastDoseTRUE = (TIME > LastDoseStart) AND (TIME < LastDoseEnd)$
 $INIT N = 1$
 $NEXT N = N + (LastDoseTrue)$;determines number of time steps in last dose interval
 interval

{MRK-1}
 $INIT ConcSump = ConcP$;effectively sets initial value to zero
 $NEXT ConcSump = ConcSump + (CONCP * LastDoseTrue)$;cumulative addition of concentration
 values during last dose interval
 $AveConcPLastDose = (ConcSump / N)$;calculation of average concentration during last dose interval
 $AUCp = AveConcPLastDose * RepeatT$;calculation of AUC during last dose interval
 $AUCup = AUCp * fup$;convert to unbound AUC
 $mwp = 324.38$;molecular weight
 $AUCupUM = AUCup / mwp$;convert AUC to uM

{M1}
 $INIT ConcSumm1 = ConcM1$
 $NEXT ConcSumm1 = ConcSumm1 + (CONCM1 * LastDoseTrue)$
 $AveConcM1LastDose = (ConcSumm1 / N)$
 $AUCm1 = AveConcM1LastDose * RepeatT$
 $AUCum1 = AUCm1 * fum1$
 $mwm1 = 296.33$
 $AUCum1UM = AUCum1 / mwm1$

{M2}
 $INIT ConcSumm2 = ConcM2$
 $NEXT ConcSumm2 = ConcSumm2 + (CONCM2 * LastDoseTrue)$
 $AveConcM2LastDose = (ConcSumm2 / N)$
 $AUCm2 = AveConcM2LastDose * RepeatT$
 $AUCum2 = AUCm2 * fum2$
 $mwm2 = 338.36$
 $AUCum2UM = AUCum2 / mwm2$

{-----}
{Normalise in vitro potency of M1 and M2 relative to MRK-1}

$p_IC50 = 1.2$;potency of MRK-1 nM
 $m1_IC50 = 1.8$;potency of M1 nM
 $m2_IC50 = 0.7$;potency of M2 nM

$m1_MRK1equivs = p_IC50 / m1_IC50$;calculate M1 potency in MRK-1 "equivalents"
 $m2_MRK1equivs = p_IC50 / m2_IC50$;calculate M2 potency in MRK-1 "equivalents"

{Sum of unbound AUCs for MEK-1, M1 and M2 expressed in MRK-1 "equivalents"}

$AUC_{uUMMRK1equivs} = (AUC_{upUM}) + (AUC_{um1UM} * m1_{MRK1equivs}) + (AUC_{um2UM} * m2_{MRK1equivs})$

$TargetAUC_{uUMMRK1equivs} = 16.8$;target unbound AUC equivalents for efficacy

Target = TargetAUC_{uUMMRK1equivs}